[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-venous-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-venous-insufficiency":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,105,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100548229","clinical-study-to-evaluate-the-effectiveness-and-health-economics-of-a-novel-portable-non-pneumatic-active-compression-device-npcd-for-lymphedemaphlebolymphedema-100548229",false,"NCT06418282","Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema\u002FPhlebolymphedema","An Open-label, Multi-center, Prospective VA Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema\u002FPhlebolymphedema","GRANDE","Inclusion Criteria:\n\n* Males and females ≥ 18 years of age\n* Capable and willing to sign the informed consent and deemed capable of following the study protocol\n* Subjects must have a diagnosis of unilateral or bilateral lower extremity edema or lower extremity lymphedema\u002Fphlebolymphedema as a consequence of chronic venous insufficiency\n* Subjects who have medical clearance using diagnostic confirmation through venous duplex to rule out DVT and superficial\u002Fdeep reflux\n\nExclusion Criteria:\n\n* Inability or unwillingness to participate in all aspects of study protocol and\u002For inability to provide informed consent\n* Individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy\n* Subjects must not have any diagnosed cognitive or physical impairment that would interfere with the use of the device\n* Non-ambulatory individuals\n* Female: BMI \\> 34 (5'4\", 200 lbs.)\n* Male: BMI \\> 34 (5'9\", 230 lbs.)\n* (Max circumference at patella 58 cm; Max circumference at gluteal fold 75 cm)\n* Diagnosis of lipedema\n* Diagnosis of active or recurrent cancer (\\\u003C 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer)\n* Diagnosis of acute infection (in the last four weeks)\n* Diagnosis of active\u002Fopen wound\u002Fulcer\n* Diagnosis of acute thrombophlebitis (in last 2 months)\n* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months\n* Diagnosis of pulmonary edema\n* Diagnosis of congestive heart failure (uncontrolled\u002Funcompensated)\n* Diagnosis of chronic kidney disease with acute renal failure\n* Diagnosis of epilepsy\n* Subjects with poorly controlled asthma\n* Any condition where increased venous and lymphatic return is undesirable\n* Women who are pregnant, planning a pregnancy or nursing at study entry\n* Participation in any clinical trial of an investigational substance or device during the past 30 days","ALL","18 Years","100 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","An open-label, multi-center, prospective VA study to evaluate the effectiveness and health economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for lymphedema\u002Fphlebolymphedema",[28,29,30],"Phlebolymphedema","Lymphedema","Chronic Venous Insufficiency","RECRUITING","2026-04-28",{"date":34,"type":35},"2026-05-04","ACTUAL",{"date":37,"type":35},"2024-05-13",{"date":39,"type":22},"2027-12-31",{"name":41,"class":42},"Koya Medical, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100627522","the-influence-of-laser-crossectomy-with-different-wavelengths-on-varicose-vein-progression-100627522","NCT07449728","The Influence of Laser Crossectomy With Different Wavelengths on Varicose Vein Progression","LACROSS-VVP","Inclusion Criteria:\n\n* Age \\>18 years\n* Primary VVs of Clinical Etiology Anatomy Pathophysiology (CEAP) clinical class of C2-C6\n* Reflux along the GSV trunk lasting \\>0.5 sec.\n* GSV trunk diameter ≤12 mm\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Primary reflux outside the GSV trunk (including combined reflux)\n* History of deep or superficial vein thrombosis\n* Deep vein reflux\n* Non-thrombotic or post-thrombotic venous obstruction\n* Pelvic venous insufficiency\n* Use of oral anticoagulants\n* Indication for pharmacological prophylaxis after EVLT\n* Inability to use radial fiber of 1.4-1.57 mm at the surgeon's discretion\n* Refusal to participate in the study",{"count":52,"type":22},400,[25],"Technically successful laser crossectomy will reduce the risk of reflux recurrence at the sapheno-femoral junction without increasing the risk of endovenous heat-induced thrombosis, which may positively impact the likelihood of ultrasound- or clinical-recurrence of varicose veins. Similar technical efficacy is expected for laser crossectomy at 1940 nm and 1470 nm. A possible advantage of the 1940 nm wavelength in terms of postoperative pain intensity and the risk of adverse events cannot be ruled out.",[56,30],"Varicose Veins",[58,59,60,61,62],"Varicose veins","Endovenous laser treatment","Reflux","Recurrence","Crossectomy","2026-02-26",{"date":65,"type":35},"2026-03-04",{"date":67,"type":35},"2026-01-20",{"date":69,"type":22},"2029-01-20",{"name":71,"class":72},"Pirogov Russian National Research Medical University","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100622936","phase-4-calcium-dobesilate-after-radiofrequency-ablation-for-varicose-veins-100622936","NCT07390097","Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins","Effect of Perioperative Calcium Dobesilate on Postprocedural Pain, Symptom Relief, and Quality of Life After Radiofrequency Ablation for Great Saphenous Vein Insufficiency: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-70 years\n* Symptomatic primary varicose veins (CEAP classification C2-C4)\n* Great saphenous vein insufficiency confirmed by duplex ultrasound (reflux \\>0.5 seconds)\n* Great saphenous vein diameter 5-12 mm\n* Scheduled for radiofrequency ablation\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* History of deep vein thrombosis\n* Peripheral arterial disease (ABI \\\u003C0.9)\n* Active venous ulcer (CEAP C6)\n* Pregnancy or breastfeeding\n* Severe renal or hepatic insufficiency\n* Known allergy to calcium dobesilate\n* Use of venoactive drugs within the past 4 weeks\n* Current anticoagulant therapy\n* Previous venous intervention on the same limb\n* Bilateral disease requiring simultaneous treatment\n* Inability to comply with follow-up schedule","70 Years",{"count":82,"type":22},250,[84],"PHASE4","This study evaluates whether calcium dobesilate, a venoactive drug, improves recovery after radiofrequency ablation (RFA) for varicose veins. Patients with great saphenous vein insufficiency undergoing RFA will be randomly assigned to receive either calcium dobesilate (500 mg twice daily) or standard care alone. The treatment starts 7 days before the procedure and continues for 30 days after. The primary outcome is postoperative pain at day 7. Secondary outcomes include pain at days 14 and 30, quality of life, ecchymosis, and return to daily activities.",[87,88,30],"Varicose Veins Leg","Great Saphenous Vein Insufficiency",[90,91,92,93,94],"Calcium Dobesilate","Radiofrequency Ablation","Venoactive Drug","Postoperative Pain","Quality of Life","NOT_YET_RECRUITING","2026-01-28",{"date":98,"type":35},"2026-02-05",{"date":100,"type":22},"2026-02-28",{"date":102,"type":22},"2026-11",{"name":104,"class":72},"Oguz Arslanturk",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100533945","phase-2-clinical-study-in-adult-patients-with-purulent-inflammatory-processes-of-the-skin-and-soft-tissues-phase-i-ii-of-the-wound-process-100533945","NCT06232421","Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process","A Prospective, Parallel, Single-blind Clinical Study Using Stratified Randomization of the Effectiveness, Tolerability and Safety of the Medicinal Product \"Foscelantan, Medicinal Plate 4.0x5.0 cm in Package No. 1\" Produced by UNITEKHPROM BSU, Republic of Belarus, in Comparison With the Medicinal Product Povidone- Iodine Produced by BelAseptika JSC, in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues Due to the Neuropathic Form of Diabetic Foot Syndrome or Chronic Venous Insufficiency, Phase I-II of the Wound Process","OLENKRON-01","Inclusion Criteria:\n\n* The presence of purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome (Main diagnosis: Diabetes mellitus type I or II, clinical metabolic compensation\u002Fsubcompensation, class I - II according to the Wagner classification) or chronic venous insufficiency (Main diagnosis: Varicose veins dilatation of the veins of the lower extremities, class C6 according to the CEAP classification), phase I-II of the wound process\n* The size of the ulcerative defect is from 1 cm² to 20 cm²\n* Secondary type of wound healing\n* Absence of exposed bones and tendons in the wound\n* Absence of severe concomitant diseases in the stage of decompensation, oncological diseases, as well as diseases requiring steroid therapy\n* Availability of written informed consent from the patient to participate in the study\n* The patient's ability to follow the instructions of the research physician and comply with the study regimen\n\nExclusion Criteria:\n\n* Individual intolerance or hypersensitivity reactions to the components of the drug Foscelantan\n* Neuroischemic form of diabetic foot syndrome\n* The presence of serious concomitant pathology (severe form of renal and hepatic failure, systemic connective tissue diseases, severe cardiovascular insufficiency), history and current mental illness\n* The need to constantly take drugs from the list of prohibited therapies\n* Participation of the patient in another clinical trial within 3 months before the current clinical trial\n* Acute bleeding\n* Level of peripheral blood leukocytes less than 1.5 × 109 per l, platelets less than 75.0 × 109 per l.\n* Hemoglobin less than 80g per l.\n* Positive tests for syphilis, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n* Severe liver dysfunction - AST or ALT levels exceed the upper limit of normal by 5 times or more, bilirubin ≥ 2.0 mg\u002FdL (34.2 µmol\u002FL).\n* Severe renal dysfunction - creatinine 2 times higher than reference values\n* Diabetes mellitus in a state of clinical and metabolic decompensation\n* Pregnant and breastfeeding women\n* At one\\'s own request without explaining the reasons for the action.\n* At the request of the research physician, if the research subject violates the protocol requirements for diet, consumption of alcoholic beverages, and medications without the prescription of the research physician.\n* For reasons independent of the study subject and the research physician, when a study subject develops drug intolerance and other life-threatening or requiring emergency pharmacotherapy adverse reactions to the administration of the study drug.\n* The need to prescribe drugs from the list of prohibited treatments.",{"count":114,"type":22},224,[116,117],"PHASE2","PHASE3","The purpose of this study is to estimate efficiency, tolerance, safety of \"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1\" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.",[120,30],"Diabetic Foot Infections",[122,123,124,125,126],"diabetic foot infection","chronic venous insuffiency","lidocaine","cellulose","miramistin","2025-07-22",{"date":129,"type":35},"2025-07-25",{"date":131,"type":22},"2025-11",{"date":133,"type":22},"2026-05",{"name":135,"class":72},"Research Institute for Physical Chemical Problems of the Belarusian State University",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100381952","feasibility-of-the-innovein-valve-and-delivery-system-for-chronic-venous-insufficiency-100381952","NCT04253301","Feasibility of the InnoVein Valve and Delivery System for Chronic Venous Insufficiency","Key Inclusion Criteria:\n\n* Willing and able to provide written Informed Consent\n* Diagnosis of symptomatic non-obstructive chronic valvular insufficiency of the femoral vein\n* Willing and medically able to receive intraprocedural and post-procedural anticoagulation medication\n* Life expectancy \\>1yr\n* Reflux time \\>1s in the superficial femoral and\u002For popliteal vein\n\nKey Exclusion Criteria:\n\n* Any prior deep vein intervention within 6 months prior to the Index Procedure\n* History of 2+ DVTs\n* Inadequate inflow to the femoral vein or inadequate outflow through the femoral vein, iliac vein, or IVC\n* Current IVC Placement\n* History of pulmonary embolism within 6 months\n* Conditions that increase the risk of device thrombosis or patient bleeding\n* Any planned surgical or interventional procedure within 30 days prior to or after the Index Procedure\n* Investigator or sponsor believes the subject would not benefit, would not be appropriate, be unable to follow-up, or be at high risk for non-compliance with the protocol",{"count":5,"type":22},[25],"This objective of this feasibility study is to evaluate the safety of the InnoVein Valve and Delivery System for treatment of chronic venous insufficiency.",[30],"2021-09-15",{"date":149,"type":35},"2021-09-17",{"date":151,"type":35},"2020-01-15",{"date":153,"type":22},"2027-01-15",{"name":155,"class":42},"InnoVein",3]